GSK GSK · NYSE
$50.06 -1.13% (-$0.57)
Summary
67 / 100 · Bulios Score
What speaks for it
- Out of every 100 GBP of revenue, 15 GBP is left as net profit.
- It earns 14 GBP a year on every 100 GBP of invested capital.
- You pay 15.4 GBP for 1 GBP of yearly profit, little for its sector.
What to watch
- Earnings per share fell by 8.8% a year over the last 3 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 15.4 GBP for 1 GBP of yearly profit. Over the last five years it was 11.3 GBP on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (GBP)
Diluted EPS (GBP)
- Analyst estimate
Revenue grew by 6.0% a year over 5 years. Over the last 3 years it grew by 3.7% a year. For the next fiscal year analysts expect revenue to grow by 4.4%.
Growth in detailDoes it make money?
Very wellWhere 100 GBP of revenue goes
- Cost of sales 27 GBP
- Research and development 28 GBP
- Sales and administration 24 GBP
- Taxes and other 6.2 GBP
- Net profit 15 GBP
Net profit, industry median (Drug Manufacturers - General) 14 GBP
Out of every 100 GBP of revenue, 15 GBP is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 3.69%
- Paid out of profit
- 57%
- Raised in a row
- 2 years
You receive $1.82 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Neutral- Buy 9
- Hold 16
- Sell 4
Today's price within the analysts' price targets
The average target of $60 is 20% above today's price. 31% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2022By product
- Sub Total 100%
By region
- International 55%
- Europe 45%
Sub Total brings in 100% of revenue.
Segments in detail